ID   SHAN3_RAT               Reviewed;        1740 AA.
AC   Q9JLU4; Q9WUY7; Q9WV47;
DT   26-JUL-2002, integrated into UniProtKB/Swiss-Prot.
DT   19-FEB-2014, sequence version 3.
DT   02-OCT-2024, entry version 202.
DE   RecName: Full=SH3 and multiple ankyrin repeat domains protein 3;
DE            Short=Shank3;
DE   AltName: Full=Proline-rich synapse-associated protein 2;
DE            Short=ProSAP2;
DE   AltName: Full=SPANK-2;
GN   Name=Shank3; Synonyms=Prosap2;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INTERACTION WITH DLGAP1 AND DLG4,
RP   AND TISSUE SPECIFICITY.
RX   PubMed=10527873; DOI=10.1006/bbrc.1999.1489;
RA   Boeckers T.M., Winter C., Smalla K.-H., Kreutz M.R., Bockmann J.,
RA   Seidenbecher C., Garner C.C., Gundelfinger E.D.;
RT   "Proline-rich synapse-associated proteins ProSAP1 and ProSAP2 interact with
RT   synaptic proteins of the SAPAP/GKAP family.";
RL   Biochem. Biophys. Res. Commun. 264:247-252(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INTERACTION WITH DLGAP1 AND CTTN,
RP   AND OLIGOMERIZATION.
RC   STRAIN=Sprague-Dawley; TISSUE=Hippocampus;
RX   PubMed=10433268; DOI=10.1016/s0896-6273(00)80809-0;
RA   Naisbitt S., Kim E., Tu J.C., Xiao B., Sala C., Valtschanoff J.,
RA   Weinberg R.J., Worley P.F., Sheng M.;
RT   "Shank, a novel family of postsynaptic density proteins that binds to the
RT   NMDA receptor/PSD-95/GKAP complex and cortactin.";
RL   Neuron 23:569-582(1999).
RN   [3]
RP   PARTIAL NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RC   TISSUE=Brain;
RX   PubMed=10958799; DOI=10.1074/jbc.m006448200;
RA   Tobaben S., Suedhof T.C., Stahl B.;
RT   "The G protein-coupled receptor CL1 interacts directly with proteins of the
RT   Shank family.";
RL   J. Biol. Chem. 275:36204-36210(2000).
RN   [4]
RP   INTERACTION WITH HOMER1; HOMER2; HOMER3; DLGAP1; MGLUR1A AND MGLUR5, AND
RP   MUTAGENESIS OF PRO-1311 AND PHE-1314.
RX   PubMed=10433269; DOI=10.1016/s0896-6273(00)80810-7;
RA   Tu J.C., Xiao B., Naisbitt S., Yuan J.P., Petralia R.S., Brakeman P.,
RA   Doan A., Aakalu V.K., Lanahan A.A., Sheng M., Worley P.F.;
RT   "Coupling of mGluR/Homer and PSD-95 complexes by the Shank family of
RT   postsynaptic density proteins.";
RL   Neuron 23:583-592(1999).
RN   [5]
RP   REVIEW.
RX   PubMed=10806096; DOI=10.1242/jcs.113.11.1851;
RA   Sheng M., Kim E.;
RT   "The Shank family of scaffold proteins.";
RL   J. Cell Sci. 113:1851-1856(2000).
RN   [6]
RP   INTERACTION WITH DBNL, AND TISSUE SPECIFICITY.
RX   PubMed=15014124; DOI=10.1523/jneurosci.5479-03.2004;
RA   Qualmann B., Boeckers T.M., Jeromin M., Gundelfinger E.D., Kessels M.M.;
RT   "Linkage of the actin cytoskeleton to the postsynaptic density via direct
RT   interactions of Abp1 with the ProSAP/Shank family.";
RL   J. Neurosci. 24:2481-2495(2004).
RN   [7]
RP   INTERACTION WITH LZTS3, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=16522626; DOI=10.1074/jbc.m601101200;
RA   Wendholt D., Spilker C., Schmitt A., Dolnik A., Smalla K.H., Proepper C.,
RA   Bockmann J., Sobue K., Gundelfinger E.D., Kreutz M.R., Boeckers T.M.;
RT   "ProSAP-interacting protein 1 (ProSAPiP1), a novel protein of the
RT   postsynaptic density that links the spine-associated Rap-Gap (SPAR) to the
RT   scaffolding protein ProSAP2/Shank3.";
RL   J. Biol. Chem. 281:13805-13816(2006).
RN   [8]
RP   INTERACTION WITH ABI1, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND
RP   MUTAGENESIS OF PRO-677; PRO-678; PRO-679; PRO-680 AND PRO-684.
RX   PubMed=17304222; DOI=10.1038/sj.emboj.7601569;
RA   Proepper C., Johannsen S., Liebau S., Dahl J., Vaida B., Bockmann J.,
RA   Kreutz M.R., Gundelfinger E.D., Boeckers T.M.;
RT   "Abelson interacting protein 1 (Abi-1) is essential for dendrite
RT   morphogenesis and synapse formation.";
RL   EMBO J. 26:1397-1409(2007).
RN   [9]
RP   FUNCTION IN MGLUR5 SIGNALING REGULATION, AND TISSUE SPECIFICITY.
RX   PubMed=21795692; DOI=10.1074/jbc.m111.258384;
RA   Verpelli C., Dvoretskova E., Vicidomini C., Rossi F., Chiappalone M.,
RA   Schoen M., Di Stefano B., Mantegazza R., Broccoli V., Boeckers T.M.,
RA   Dityatev A., Sala C.;
RT   "Importance of Shank3 protein in regulating metabotropic glutamate receptor
RT   5 (mGluR5) expression and signaling at synapses.";
RL   J. Biol. Chem. 286:34839-34850(2011).
RN   [10]
RP   FUNCTION, AND MUTAGENESIS OF ARG-12; ARG-300 AND GLN-321.
RX   PubMed=23100419; DOI=10.1523/jneurosci.2215-12.2012;
RA   Arons M.H., Thynne C.J., Grabrucker A.M., Li D., Schoen M., Cheyne J.E.,
RA   Boeckers T.M., Montgomery J.M., Garner C.C.;
RT   "Autism-associated mutations in ProSAP2/Shank3 impair synaptic transmission
RT   and neurexin-neuroligin-mediated transsynaptic signaling.";
RL   J. Neurosci. 32:14966-14978(2012).
RN   [11]
RP   FUNCTION, ACTIN-BINDING, SUBCELLULAR LOCATION, AND MUTAGENESIS OF ARG-12;
RP   ARG-300 AND GLN-321.
RX   PubMed=21606927; DOI=10.1038/mp.2011.57;
RA   Durand C.M., Perroy J., Loll F., Perrais D., Fagni L., Bourgeron T.,
RA   Montcouquiol M., Sans N.;
RT   "SHANK3 mutations identified in autism lead to modification of dendritic
RT   spine morphology via an actin-dependent mechanism.";
RL   Mol. Psychiatry 17:71-84(2012).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-375; SER-387; SER-394;
RP   TYR-931; THR-1131; SER-1135; SER-1160; SER-1167; THR-1235; SER-1254;
RP   SER-1421; SER-1511 AND SER-1644, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
RN   [13]
RP   FUNCTION, DOMAIN, INTERACTION WITH SHARPIN AND SPTAN1, SUBCELLULAR
RP   LOCATION, AND MUTAGENESIS OF LEU-68; ARG-300 AND GLN-321.
RX   PubMed=23897824; DOI=10.1074/jbc.m112.424747;
RA   Mameza M.G., Dvoretskova E., Bamann M., Hoenck H.H., Gueler T.,
RA   Boeckers T.M., Schoen M., Verpelli C., Sala C., Barsukov I., Dityatev A.,
RA   Kreienkamp H.J.;
RT   "SHANK3 gene mutations associated with autism facilitate ligand binding to
RT   the Shank3 ankyrin repeat region.";
RL   J. Biol. Chem. 288:26697-26708(2013).
RN   [14]
RP   FUNCTION IN NMDA RECEPTOR SIGNALING REGULATION.
RX   PubMed=24089484; DOI=10.1523/jneurosci.1175-13.2013;
RA   Duffney L.J., Wei J., Cheng J., Liu W., Smith K.R., Kittler J.T., Yan Z.;
RT   "Shank3 deficiency induces NMDA receptor hypofunction via an actin-
RT   dependent mechanism.";
RL   J. Neurosci. 33:15767-15778(2013).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 1674-1740.
RX   PubMed=16439662; DOI=10.1126/science.1118995;
RA   Baron M.K., Boeckers T.M., Vaida B., Faham S., Gingery M., Sawaya M.R.,
RA   Salyer D., Gundelfinger E.D., Bowie J.U.;
RT   "An architectural framework that may lie at the core of the postsynaptic
RT   density.";
RL   Science 311:531-535(2006).
CC   -!- FUNCTION: Major scaffold postsynaptic density protein which interacts
CC       with multiple proteins and complexes to orchestrate the dendritic spine
CC       and synapse formation, maturation and maintenance. Interconnects
CC       receptors of the postsynaptic membrane including NMDA-type and
CC       metabotropic glutamate receptors via complexes with GKAP/PSD-95 and
CC       HOMER, respectively, and the actin-based cytoskeleton. Plays a role in
CC       the structural and functional organization of the dendritic spine and
CC       synaptic junction through the interaction with Arp2/3 and WAVE1 complex
CC       as well as the promotion of the F-actin clusters. By way of this
CC       control of actin dynamics, participates in the regulation of developing
CC       neurons growth cone motility and the NMDA receptor-signaling. Also
CC       modulates GRIA1 exocytosis and GRM5/MGLUR5 expression and signaling to
CC       control the AMPA and metabotropic glutamate receptor-mediated synaptic
CC       transmission and plasticity. May be required at an early stage of
CC       synapse formation and be inhibited by IGF1 to promote synapse
CC       maturation. {ECO:0000269|PubMed:21606927, ECO:0000269|PubMed:21795692,
CC       ECO:0000269|PubMed:23100419, ECO:0000269|PubMed:23897824,
CC       ECO:0000269|PubMed:24089484}.
CC   -!- SUBUNIT: May homomultimerize via its SAM domain. Interacts with BAIAP2,
CC       DBNL and SLC17A7/VGLUT1. Interacts with DLGAP1/GKAP, GRM1/MGLUR1,
CC       GRM5/MGLUR5 and LZTS3 C-termini via its PDZ domain. Interacts with
CC       ABI1, HOMER1, HOMER2, HOMER3 and CTTN/cortactin SH3 domain. Is part of
CC       a complex with DLG4/PSD-95 and DLGAP1/GKAP. Interacts (via PDZ domain)
CC       with the GRIA1 subunit of the AMPA receptor (via PDZ-binding motif).
CC       Interacts with WASF1 and CYFIP2; the interactions mediate the
CC       association of SHANK3 with the WAVE1 complex. Interacts with ARPC2; the
CC       interaction probably mediates the association of SHANK3 with the Arp2/3
CC       complex. Interacts (via ANK repeats) with SHARPIN and SPTAN1. Interacts
CC       (via PDZ domain) with ARHGAP44 (probably via PDZ-binding motif); the
CC       interaction takes place in dendritic spines and promotes GRIA1
CC       exocytosis. Interacts with CAMK2A (By similarity). Interacts with DIP2A
CC       (By similarity). {ECO:0000250|UniProtKB:Q4ACU6,
CC       ECO:0000250|UniProtKB:Q9BYB0, ECO:0000269|PubMed:10433268,
CC       ECO:0000269|PubMed:10433269, ECO:0000269|PubMed:10527873,
CC       ECO:0000269|PubMed:15014124, ECO:0000269|PubMed:16522626,
CC       ECO:0000269|PubMed:17304222, ECO:0000269|PubMed:23897824}.
CC   -!- INTERACTION:
CC       Q9JLU4; Q9QZM5: Abi1; NbExp=7; IntAct=EBI-6271152, EBI-920097;
CC       Q9JLU4; Q9JLU4: Shank3; NbExp=2; IntAct=EBI-6271152, EBI-6271152;
CC       Q9JLU4; Q9ES28-2: Arhgef7; Xeno; NbExp=2; IntAct=EBI-6271152, EBI-8620514;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Postsynaptic density. Cell projection,
CC       dendritic spine. Note=In neuronal cells, extends into the region
CC       subjacent to the PSD.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage, Alternative splicing; Named isoforms=3;
CC         Comment=Additional isoforms seem to exist. These isoforms may be the
CC         product of multiple intragenic promoter and/or alternative splicing.;
CC       Name=2;
CC         IsoId=Q9JLU4-1; Sequence=Displayed;
CC       Name=1; Synonyms=A;
CC         IsoId=Q9JLU4-2; Sequence=VSP_006089;
CC       Name=3;
CC         IsoId=Q9JLU4-3; Sequence=VSP_006087, VSP_006088;
CC   -!- TISSUE SPECIFICITY: Widely expressed in brain (at protein level).
CC       {ECO:0000269|PubMed:10527873, ECO:0000269|PubMed:15014124,
CC       ECO:0000269|PubMed:16522626, ECO:0000269|PubMed:17304222,
CC       ECO:0000269|PubMed:21795692}.
CC   -!- DOMAIN: In isoform 1, the N-terminal region preceding the ANK repeats
CC       interacts with the 6 ANK repeats in an intramolecular manner, thereby
CC       restricting access to ligands, such as SHARPIN and SPTAN1.
CC       {ECO:0000269|PubMed:23897824}.
CC   -!- SIMILARITY: Belongs to the SHANK family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAD42976.1; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF133301; AAF61375.1; -; mRNA.
DR   EMBL; AJ133120; CAB45688.1; -; mRNA.
DR   EMBL; AF159047; AAD42976.1; ALT_FRAME; mRNA.
DR   RefSeq; NP_067708.1; NM_021676.1.
DR   PDB; 2F3N; X-ray; 2.10 A; A/B/C=1674-1740.
DR   PDB; 2F44; X-ray; 2.40 A; A/B/C=1674-1740.
DR   PDB; 5G4X; X-ray; 2.17 A; A=1-348.
DR   PDB; 5O99; X-ray; 0.87 A; A/B=470-528.
DR   PDB; 5OVA; X-ray; 2.30 A; A/B=570-664.
DR   PDB; 5OVC; X-ray; 1.55 A; A=570-664.
DR   PDB; 5OVP; X-ray; 1.50 A; A=570-664.
DR   PDB; 5OVV; X-ray; 1.40 A; A=570-664.
DR   PDB; 6EXJ; X-ray; 1.80 A; A/C=570-664.
DR   PDBsum; 2F3N; -.
DR   PDBsum; 2F44; -.
DR   PDBsum; 5G4X; -.
DR   PDBsum; 5O99; -.
DR   PDBsum; 5OVA; -.
DR   PDBsum; 5OVC; -.
DR   PDBsum; 5OVP; -.
DR   PDBsum; 5OVV; -.
DR   PDBsum; 6EXJ; -.
DR   AlphaFoldDB; Q9JLU4; -.
DR   SASBDB; Q9JLU4; -.
DR   SMR; Q9JLU4; -.
DR   BioGRID; 248756; 16.
DR   IntAct; Q9JLU4; 11.
DR   MINT; Q9JLU4; -.
DR   STRING; 10116.ENSRNOP00000071295; -.
DR   iPTMnet; Q9JLU4; -.
DR   PhosphoSitePlus; Q9JLU4; -.
DR   PaxDb; 10116-ENSRNOP00000041083; -.
DR   ABCD; Q9JLU4; 4 sequenced antibodies.
DR   GeneID; 59312; -.
DR   KEGG; rno:59312; -.
DR   AGR; RGD:69264; -.
DR   CTD; 85358; -.
DR   RGD; 69264; Shank3.
DR   eggNOG; KOG0504; Eukaryota.
DR   eggNOG; KOG4375; Eukaryota.
DR   InParanoid; Q9JLU4; -.
DR   OrthoDB; 2247290at2759; -.
DR   Reactome; R-RNO-6794361; Neurexins and neuroligins.
DR   Reactome; R-RNO-8853659; RET signaling.
DR   EvolutionaryTrace; Q9JLU4; -.
DR   PRO; PR:Q9JLU4; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0060170; C:ciliary membrane; IDA:BHF-UCL.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0043197; C:dendritic spine; IBA:GO_Central.
DR   GO; GO:0098978; C:glutamatergic synapse; IDA:SynGO.
DR   GO; GO:0043005; C:neuron projection; ISS:BHF-UCL.
DR   GO; GO:0044309; C:neuron spine; ISS:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; ISS:BHF-UCL.
DR   GO; GO:0014069; C:postsynaptic density; IDA:UniProtKB.
DR   GO; GO:0099092; C:postsynaptic density, intracellular component; IDA:SynGO.
DR   GO; GO:0003779; F:actin binding; IEA:UniProtKB-KW.
DR   GO; GO:0001664; F:G protein-coupled receptor binding; IPI:RGD.
DR   GO; GO:0042802; F:identical protein binding; IDA:RGD.
DR   GO; GO:0035255; F:ionotropic glutamate receptor binding; ISS:BHF-UCL.
DR   GO; GO:0044877; F:protein-containing complex binding; IDA:RGD.
DR   GO; GO:0097110; F:scaffold protein binding; IPI:BHF-UCL.
DR   GO; GO:0017124; F:SH3 domain binding; IPI:RGD.
DR   GO; GO:0098919; F:structural constituent of postsynaptic density; IDA:SynGO.
DR   GO; GO:0030160; F:synaptic receptor adaptor activity; IDA:BHF-UCL.
DR   GO; GO:0008270; F:zinc ion binding; IDA:RGD.
DR   GO; GO:0030534; P:adult behavior; ISO:RGD.
DR   GO; GO:0097113; P:AMPA glutamate receptor clustering; ISS:BHF-UCL.
DR   GO; GO:0008306; P:associative learning; ISO:RGD.
DR   GO; GO:0048854; P:brain morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0060997; P:dendritic spine morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0001838; P:embryonic epithelial tube formation; ISO:RGD.
DR   GO; GO:0035640; P:exploration behavior; ISO:RGD.
DR   GO; GO:0010467; P:gene expression; ISO:RGD.
DR   GO; GO:0014009; P:glial cell proliferation; ISO:RGD.
DR   GO; GO:0097117; P:guanylate kinase-associated protein clustering; ISS:BHF-UCL.
DR   GO; GO:0007612; P:learning; ISS:BHF-UCL.
DR   GO; GO:0007611; P:learning or memory; ISO:RGD.
DR   GO; GO:0040011; P:locomotion; ISO:RGD.
DR   GO; GO:0007626; P:locomotory behavior; ISO:RGD.
DR   GO; GO:0035641; P:locomotory exploration behavior; ISS:BHF-UCL.
DR   GO; GO:0060292; P:long-term synaptic depression; ISO:RGD.
DR   GO; GO:0060291; P:long-term synaptic potentiation; ISO:RGD.
DR   GO; GO:0099562; P:maintenance of postsynaptic density structure; IC:SynGO.
DR   GO; GO:0000165; P:MAPK cascade; ISS:BHF-UCL.
DR   GO; GO:0007613; P:memory; ISS:BHF-UCL.
DR   GO; GO:0050804; P:modulation of chemical synaptic transmission; ISO:RGD.
DR   GO; GO:0032232; P:negative regulation of actin filament bundle assembly; ISS:BHF-UCL.
DR   GO; GO:0045794; P:negative regulation of cell volume; ISS:BHF-UCL.
DR   GO; GO:0061351; P:neural precursor cell proliferation; ISO:RGD.
DR   GO; GO:0050885; P:neuromuscular process controlling balance; ISS:BHF-UCL.
DR   GO; GO:0097114; P:NMDA glutamate receptor clustering; ISS:BHF-UCL.
DR   GO; GO:0060999; P:positive regulation of dendritic spine development; ISS:BHF-UCL.
DR   GO; GO:2000463; P:positive regulation of excitatory postsynaptic potential; ISS:BHF-UCL.
DR   GO; GO:1900451; P:positive regulation of glutamate receptor signaling pathway; IMP:RGD.
DR   GO; GO:0048170; P:positive regulation of long-term neuronal synaptic plasticity; ISS:BHF-UCL.
DR   GO; GO:1900273; P:positive regulation of long-term synaptic potentiation; ISS:BHF-UCL.
DR   GO; GO:0051835; P:positive regulation of synapse structural plasticity; ISS:BHF-UCL.
DR   GO; GO:0051968; P:positive regulation of synaptic transmission, glutamatergic; ISS:BHF-UCL.
DR   GO; GO:0097107; P:postsynaptic density assembly; ISS:BHF-UCL.
DR   GO; GO:1904717; P:regulation of AMPA glutamate receptor clustering; ISO:RGD.
DR   GO; GO:2000822; P:regulation of behavioral fear response; ISS:BHF-UCL.
DR   GO; GO:0061001; P:regulation of dendritic spine morphogenesis; ISS:BHF-UCL.
DR   GO; GO:2000821; P:regulation of grooming behavior; ISO:RGD.
DR   GO; GO:1900452; P:regulation of long-term synaptic depression; ISS:BHF-UCL.
DR   GO; GO:1900271; P:regulation of long-term synaptic potentiation; ISS:BHF-UCL.
DR   GO; GO:0099175; P:regulation of postsynapse organization; IDA:SynGO.
DR   GO; GO:0048167; P:regulation of synaptic plasticity; ISO:RGD.
DR   GO; GO:0097396; P:response to interleukin-17; ISO:RGD.
DR   GO; GO:0035176; P:social behavior; ISS:BHF-UCL.
DR   GO; GO:0021773; P:striatal medium spiny neuron differentiation; ISS:BHF-UCL.
DR   GO; GO:0007416; P:synapse assembly; ISS:BHF-UCL.
DR   GO; GO:0042297; P:vocal learning; ISO:RGD.
DR   GO; GO:0071625; P:vocalization behavior; ISS:BHF-UCL.
DR   CDD; cd00992; PDZ_signaling; 1.
DR   CDD; cd09506; SAM_Shank1_2_3; 1.
DR   Gene3D; 2.30.42.10; -; 1.
DR   Gene3D; 1.25.40.20; Ankyrin repeat-containing domain; 2.
DR   Gene3D; 2.30.30.40; SH3 Domains; 1.
DR   Gene3D; 1.10.150.50; Transcription Factor, Ets-1; 1.
DR   InterPro; IPR002110; Ankyrin_rpt.
DR   InterPro; IPR036770; Ankyrin_rpt-contain_sf.
DR   InterPro; IPR001478; PDZ.
DR   InterPro; IPR041489; PDZ_6.
DR   InterPro; IPR036034; PDZ_sf.
DR   InterPro; IPR001660; SAM.
DR   InterPro; IPR013761; SAM/pointed_sf.
DR   InterPro; IPR036028; SH3-like_dom_sf.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR051569; SHANK.
DR   PANTHER; PTHR24135; SH3 AND MULTIPLE ANKYRIN REPEAT DOMAINS PROTEIN; 1.
DR   PANTHER; PTHR24135:SF4; SH3 AND MULTIPLE ANKYRIN REPEAT DOMAINS PROTEIN 3; 1.
DR   Pfam; PF12796; Ank_2; 2.
DR   Pfam; PF17820; PDZ_6; 1.
DR   Pfam; PF00536; SAM_1; 1.
DR   Pfam; PF07653; SH3_2; 1.
DR   SMART; SM00248; ANK; 5.
DR   SMART; SM00228; PDZ; 1.
DR   SMART; SM00454; SAM; 1.
DR   SMART; SM00326; SH3; 1.
DR   SUPFAM; SSF48403; Ankyrin repeat; 1.
DR   SUPFAM; SSF50156; PDZ domain-like; 1.
DR   SUPFAM; SSF47769; SAM/Pointed domain; 1.
DR   SUPFAM; SSF50044; SH3-domain; 1.
DR   PROSITE; PS50297; ANK_REP_REGION; 1.
DR   PROSITE; PS50088; ANK_REPEAT; 4.
DR   PROSITE; PS50106; PDZ; 1.
DR   PROSITE; PS50105; SAM_DOMAIN; 1.
DR   PROSITE; PS50002; SH3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Actin-binding; Alternative promoter usage;
KW   Alternative splicing; ANK repeat; Cell projection; Coiled coil; Cytoplasm;
KW   Methylation; Phosphoprotein; Reference proteome; Repeat; SH3 domain;
KW   SH3-binding; Synapse.
FT   CHAIN           1..1740
FT                   /note="SH3 and multiple ankyrin repeat domains protein 3"
FT                   /id="PRO_0000174676"
FT   REPEAT          148..181
FT                   /note="ANK 1"
FT   REPEAT          182..214
FT                   /note="ANK 2"
FT   REPEAT          215..245
FT                   /note="ANK 3"
FT   REPEAT          249..278
FT                   /note="ANK 4"
FT   REPEAT          282..311
FT                   /note="ANK 5"
FT   REPEAT          315..345
FT                   /note="ANK 6"
FT   DOMAIN          470..529
FT                   /note="SH3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00192"
FT   DOMAIN          570..664
FT                   /note="PDZ"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00143"
FT   DOMAIN          1677..1740
FT                   /note="SAM"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00184"
FT   REGION          1..75
FT                   /note="Intramolecular interaction with the ANK repeats"
FT   REGION          354..466
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          664..687
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          677..684
FT                   /note="Required for interaction with ABI1"
FT                   /evidence="ECO:0000269|PubMed:17304222"
FT   REGION          759..855
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          868..1053
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1115..1199
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1211..1463
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1476..1518
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1556..1594
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1637..1673
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          1495..1515
FT                   /evidence="ECO:0000255"
FT   MOTIF           1411..1417
FT                   /note="SH3-binding"
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        402..418
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        440..464
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        778..792
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        813..847
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1177..1195
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1322..1344
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1368..1401
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1434..1458
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1496..1510
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1648..1662
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         122
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q4ACU6"
FT   MOD_RES         373
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q4ACU6"
FT   MOD_RES         375
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         387
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         394
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         482
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q4ACU6"
FT   MOD_RES         555
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q4ACU6"
FT   MOD_RES         694
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q4ACU6"
FT   MOD_RES         781
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q4ACU6"
FT   MOD_RES         790
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q4ACU6"
FT   MOD_RES         801
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q4ACU6"
FT   MOD_RES         891
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q4ACU6"
FT   MOD_RES         898
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q4ACU6"
FT   MOD_RES         913
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9BYB0"
FT   MOD_RES         931
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         966
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q4ACU6"
FT   MOD_RES         1131
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         1135
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         1160
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         1164
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9BYB0"
FT   MOD_RES         1167
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         1235
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         1254
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         1421
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         1511
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         1522
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q4ACU6"
FT   MOD_RES         1530
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q4ACU6"
FT   MOD_RES         1549
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q4ACU6"
FT   MOD_RES         1644
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         1646
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9BYB0"
FT   MOD_RES         1648
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9BYB0"
FT   VAR_SEQ         1129..1136
FT                   /note="SPTPVHSP -> PRRRAGMV (in isoform 3)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_006087"
FT   VAR_SEQ         1137..1740
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_006088"
FT   VAR_SEQ         1537..1545
FT                   /note="Missing (in isoform 1)"
FT                   /evidence="ECO:0000303|PubMed:10433268,
FT                   ECO:0000303|PubMed:10527873"
FT                   /id="VSP_006089"
FT   MUTAGEN         12
FT                   /note="R->C: Disrupts postsynaptic AMPA and NMDA receptor-
FT                   mediated synaptic transmission as well as transsynaptic
FT                   signaling and spine maturation."
FT                   /evidence="ECO:0000269|PubMed:21606927,
FT                   ECO:0000269|PubMed:23100419"
FT   MUTAGEN         68
FT                   /note="L->P: Slightly increases interaction with SHARPIN
FT                   and SPTAN1. No effect on localization."
FT                   /evidence="ECO:0000269|PubMed:23897824"
FT   MUTAGEN         300
FT                   /note="R->C: Disrupts postsynaptic AMPA and NMDA receptor-
FT                   mediated synaptic transmission as well as transsynaptic
FT                   signaling and spine maturation. Slightly decreases
FT                   interaction with SHARPIN and SPTAN1. No effect on
FT                   localization."
FT                   /evidence="ECO:0000269|PubMed:21606927,
FT                   ECO:0000269|PubMed:23100419, ECO:0000269|PubMed:23897824"
FT   MUTAGEN         321
FT                   /note="Q->R: Disrupts postsynaptic AMPA and NMDA receptor-
FT                   mediated synaptic transmission as well as transsynaptic
FT                   signaling and spine maturation. Disrupts axonal growth cone
FT                   motility. Slightly increases interaction with SHARPIN and
FT                   SPTAN1. No effect on localization."
FT                   /evidence="ECO:0000269|PubMed:21606927,
FT                   ECO:0000269|PubMed:23100419, ECO:0000269|PubMed:23897824"
FT   MUTAGEN         677
FT                   /note="P->A: Strongly decreases interaction with ABI1."
FT                   /evidence="ECO:0000269|PubMed:17304222"
FT   MUTAGEN         678
FT                   /note="P->A: Almost abolishes interaction with ABI1."
FT                   /evidence="ECO:0000269|PubMed:17304222"
FT   MUTAGEN         679
FT                   /note="P->A: Abolishes interaction with ABI1."
FT                   /evidence="ECO:0000269|PubMed:17304222"
FT   MUTAGEN         680
FT                   /note="P->A: Abolishes interaction with ABI1."
FT                   /evidence="ECO:0000269|PubMed:17304222"
FT   MUTAGEN         684
FT                   /note="P->A: Abolishes interaction with ABI1."
FT                   /evidence="ECO:0000269|PubMed:17304222"
FT   MUTAGEN         1311
FT                   /note="P->L: Abolishes interaction with HOMER1 isoform 3."
FT                   /evidence="ECO:0000269|PubMed:10433269"
FT   MUTAGEN         1314
FT                   /note="F->C: Abolishes interaction with HOMER1 isoform 3."
FT                   /evidence="ECO:0000269|PubMed:10433269"
FT   CONFLICT        397
FT                   /note="H -> L (in Ref. 3; AAD42976)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        706
FT                   /note="R -> G (in Ref. 3; AAD42976)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        827..832
FT                   /note="YYFDSG -> ILRLR (in Ref. 3; AAD42976)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        837..842
FT                   /note="FSPPPP -> SHHGHQ (in Ref. 3; AAD42976)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        846
FT                   /note="R -> G (in Ref. 3; AAD42976)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        888
FT                   /note="R -> G (in Ref. 3; AAD42976)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1040
FT                   /note="S -> N (in Ref. 2; AAF61375)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1087
FT                   /note="S -> N (in Ref. 2; AAF61375)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1092
FT                   /note="G -> S (in Ref. 2; AAF61375)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1262
FT                   /note="S -> N (in Ref. 2; AAF61375)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1270
FT                   /note="G -> S (in Ref. 2; AAF61375)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1273
FT                   /note="S -> N (in Ref. 2; AAF61375)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1279
FT                   /note="E -> K (in Ref. 2; AAF61375)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1294
FT                   /note="S -> N (in Ref. 2; AAF61375)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1432
FT                   /note="D -> G (in Ref. 2; AAF61375)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1640
FT                   /note="V -> A (in Ref. 2; AAF61375)"
FT                   /evidence="ECO:0000305"
FT   STRAND          9..15
FT                   /evidence="ECO:0007829|PDB:5G4X"
FT   HELIX           16..18
FT                   /evidence="ECO:0007829|PDB:5G4X"
FT   STRAND          20..26
FT                   /evidence="ECO:0007829|PDB:5G4X"
FT   HELIX           32..43
FT                   /evidence="ECO:0007829|PDB:5G4X"
FT   HELIX           50..52
FT                   /evidence="ECO:0007829|PDB:5G4X"
FT   STRAND          53..57
FT                   /evidence="ECO:0007829|PDB:5G4X"
FT   HELIX           74..76
FT                   /evidence="ECO:0007829|PDB:5G4X"
FT   STRAND          87..92
FT                   /evidence="ECO:0007829|PDB:5G4X"
FT   HELIX           104..110
FT                   /evidence="ECO:0007829|PDB:5G4X"
FT   HELIX           113..124
FT                   /evidence="ECO:0007829|PDB:5G4X"
FT   HELIX           128..136
FT                   /evidence="ECO:0007829|PDB:5G4X"
FT   TURN            146..148
FT                   /evidence="ECO:0007829|PDB:5G4X"
FT   HELIX           152..156
FT                   /evidence="ECO:0007829|PDB:5G4X"
FT   HELIX           163..171
FT                   /evidence="ECO:0007829|PDB:5G4X"
FT   HELIX           186..192
FT                   /evidence="ECO:0007829|PDB:5G4X"
FT   HELIX           196..204
FT                   /evidence="ECO:0007829|PDB:5G4X"
FT   HELIX           219..226
FT                   /evidence="ECO:0007829|PDB:5G4X"
FT   HELIX           231..238
FT                   /evidence="ECO:0007829|PDB:5G4X"
FT   HELIX           253..260
FT                   /evidence="ECO:0007829|PDB:5G4X"
FT   HELIX           263..271
FT                   /evidence="ECO:0007829|PDB:5G4X"
FT   HELIX           286..293
FT                   /evidence="ECO:0007829|PDB:5G4X"
FT   HELIX           296..304
FT                   /evidence="ECO:0007829|PDB:5G4X"
FT   HELIX           319..325
FT                   /evidence="ECO:0007829|PDB:5G4X"
FT   HELIX           329..337
FT                   /evidence="ECO:0007829|PDB:5G4X"
FT   STRAND          474..479
FT                   /evidence="ECO:0007829|PDB:5O99"
FT   STRAND          496..502
FT                   /evidence="ECO:0007829|PDB:5O99"
FT   STRAND          507..512
FT                   /evidence="ECO:0007829|PDB:5O99"
FT   STRAND          515..520
FT                   /evidence="ECO:0007829|PDB:5O99"
FT   HELIX           521..523
FT                   /evidence="ECO:0007829|PDB:5O99"
FT   STRAND          524..526
FT                   /evidence="ECO:0007829|PDB:5O99"
FT   STRAND          570..574
FT                   /evidence="ECO:0007829|PDB:5OVV"
FT   STRAND          582..587
FT                   /evidence="ECO:0007829|PDB:5OVV"
FT   HELIX           594..596
FT                   /evidence="ECO:0007829|PDB:5OVV"
FT   STRAND          601..603
FT                   /evidence="ECO:0007829|PDB:5OVA"
FT   STRAND          605..612
FT                   /evidence="ECO:0007829|PDB:5OVV"
FT   HELIX           617..620
FT                   /evidence="ECO:0007829|PDB:5OVV"
FT   STRAND          628..632
FT                   /evidence="ECO:0007829|PDB:5OVV"
FT   HELIX           642..651
FT                   /evidence="ECO:0007829|PDB:5OVV"
FT   TURN            652..654
FT                   /evidence="ECO:0007829|PDB:5OVV"
FT   STRAND          655..662
FT                   /evidence="ECO:0007829|PDB:5OVV"
FT   HELIX           1674..1676
FT                   /evidence="ECO:0007829|PDB:2F3N"
FT   HELIX           1679..1688
FT                   /evidence="ECO:0007829|PDB:2F3N"
FT   HELIX           1692..1694
FT                   /evidence="ECO:0007829|PDB:2F3N"
FT   HELIX           1695..1700
FT                   /evidence="ECO:0007829|PDB:2F3N"
FT   HELIX           1705..1710
FT                   /evidence="ECO:0007829|PDB:2F3N"
FT   HELIX           1713..1718
FT                   /evidence="ECO:0007829|PDB:2F3N"
FT   HELIX           1724..1735
FT                   /evidence="ECO:0007829|PDB:2F3N"
SQ   SEQUENCE   1740 AA;  186376 MW;  A9F486E893EA5AA0 CRC64;
     MDGPGASAVV VRVGIPDLQQ TKCLRLDPTA PVWAAKQRVL CALNHSLQDA LNYGLFQPPS
     RGRAGKFLDE ERLLQDYPPN LDTPLPYLEF RYKRRVYAQN LIDDKQFAKL HTKANLKKFM
     DYVQLHSTDK VARLLDKGLD PNFHDPDSGE CPLSLAAQLD NATDLLKVLR NGGAHLDFRT
     RDGLTAVHCA TRQRNAGALT TLLDLGASPD YKDSRGLTPL YHSALGGGDA LCCELLLHDH
     AQLGTTDENG WQEIHQACRF GHVQHLEHLL FYGANMGAQN ASGNTALHIC ALYNQESCAR
     VLLFRGANKD VRNYNSQTAF QVAIIAGNFE LAEVIKTHKD SDVVPFRETP SYAKRRRLAG
     PSGLASPRPL QRSASDINLK GDQPAASPGP TLRSLPHQLL LQRLQEEKDR DRDGEQENDI
     SGPSAGRGGH SKISPSGPGG SGPAPGPGPA SPAPPAPPPR GPKRKLYSAV PGRKFIAVKA
     HSPQGEGEIP LHRGEAVKVL SIGEGGFWEG TVKGRTGWFP ADCVEEVQMR QYDTRHETRE
     DRTKRLFRHY TVGSYDSLTS HSDYVIDDKV AILQKRDHEG FGFVLRGAKA ETPIEEFTPT
     PAFPALQYLE SVDVEGVAWK AGLRTGDFLI EVNGVNVVKV GHKQVVGLIR QGGNRLVMKV
     VSVTRKPEED SARRRAPPPP KRAPSTTLTL RSKSMTAELE ELASIRRRKG EKLDEILAVA
     AEPTLRPDIA DADSRAATVK QRPTSRRITP AEISSLFERQ GLPGPEKLPG SLRKGIPRTK
     SVGEDEKLAS LLEGRFPRST SMQDTVREGR GIPPPPQTAP PPPPAPYYFD SGPPPTFSPP
     PPPPGRAYDT VRSSFKPGLE ARLGAGAAGL YDSGTPLGPL PYPERQKRAR SMIILQDSAP
     EVGDVPRPAP AATPPERPKR RPRPSGPDSP YANLGAFSAS LFAPSKPQRR KSPLVKQLQV
     EDAQERAALA VGSPGPVGGS FAREPSPTHR GPRPGGLDYS SGEGLGLTFG GPSPGPVKER
     RLEERRRSTV FLSVGAIEGS PPSADLPSLQ PSRSIDERLL GTGATTGRDL LLPSPVSALK
     PLVGGPSLGP SGSTFIHPLT GKPLDPSSPL ALALAARERA LASQTPSRSP TPVHSPDADR
     PGPLFVDVQT RDSERGPLAS PAFSPRSPAW IPVPARREAE KPTREERKSP EDKKSMILSV
     LDTSLQRPAG LIVVHATSNG QEPNRLGAEE ERPGTPELAP TPMQAAAVAE PMPSPRAQPP
     GSIPADPGPG QGSSEEEPEL VFAVNLPPAQ LSSSDEETRE ELARIGLVPP PEEFANGILL
     ATPPPGPGPL PTTVPSPASG KPSSELPPAP ESAADSGVEE ADTRSSSDPH LETTSTISTV
     SSMSTLSSES GELTDTHTSF ADGHTFLLEK PPVPPKPKLK SPLGKGPVTF RDPLLKQSSD
     SELMAQQHHA TSTGLTSAAG PARPRYLFQR RSKLWGDPVE SRGLPGPEDD KPTVISELSS
     RLQQLNKDTR SLGEEPVGGL GSLLDPAKKS PIAAARCAVV PSAGWLFSSL GELSTISAQR
     SPGGPGGGAS YSVRPSGRYP VARRAPSPVK PASLERVEGL GAGVGGAGRP FGLTPPTILK
     SSSLSIPHEP KEVRFVVRSV SARSRSPSPS PLPSPSPGSG PSAGPRRPFQ QKPLQLWSKF
     DVGDWLESIH LGEHRDRFED HEIEGAHLPA LTKEDFVELG VTRVGHRMNI ERALRQLDGS
//
